Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E21.19 EPS (ttm)5.94 Insider Own0.02% Shs Outstand2.72B Perf Week-1.77%
Market Cap342.17B Forward P/E17.06 EPS next Y7.38 Insider Trans-20.17% Shs Float2.71B Perf Month2.50%
Income16.54B PEG3.59 EPS next Q1.76 Inst Own67.50% Short Float0.66% Perf Quarter9.70%
Sales71.89B P/S4.76 EPS this Y8.30% Inst Trans0.23% Short Ratio2.49 Perf Half Y7.32%
Book/sh25.94 P/B4.85 EPS next Y4.80% ROA11.90% Target Price125.71 Perf Year19.44%
Cash/sh15.41 P/C8.17 EPS next 5Y5.91% ROE22.90% 52W Range104.80 - 129.00 Perf YTD9.91%
Dividend3.20 P/FCF49.45 EPS past 5Y11.20% ROI17.00% 52W High-2.48% Beta0.80
Dividend %2.54% Quick Ratio2.20 Sales past 5Y2.00% Gross Margin69.90% 52W Low20.04% ATR1.31
Employees126400 Current Ratio2.50 Sales Q/Q1.70% Oper. Margin27.50% RSI (14)64.02 Volatility1.00% 1.03%
OptionableYes Debt/Eq0.39 EPS Q/Q20.10% Profit Margin23.00% Rel Volume0.71 Prev Close125.48
ShortableYes LT Debt/Eq0.32 EarningsApr 18 BMO Payout52.10% Avg Volume7.12M Price125.80
Recom2.50 SMA200.16% SMA505.76% SMA2007.40% Volume4,989,900 Change0.26%
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Mar-27-17 10:27AM  J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
10:02AM  3 Big Pharma Stocks You Don't Have to Babysit at Motley Fool
05:00AM  The $100,000 Anti-Burnout Program for CEOs
Mar-26-17 08:34AM  5 Can't Miss Dividend Hikes Coming This Spring at Forbes
Mar-25-17 05:00PM  Can This Pharma Stock Withstand the 'Trump Effect'?
Mar-24-17 06:15PM  More big brands pull ads from YouTube in widening boycott AP
05:52PM  Coca-Cola, Walmart Latest to Pull Ads From Google Amid Concerns About Offensive Content at TheStreet
05:45PM  Johnson & Johnson's CEO Believes Trump Is Missing the Point on Drug-Price Reform at Motley Fool
04:16PM  How Does Mercks Valuation Compare to Peers?
01:54PM  The Threat And Risk Of Rising Interest Rates: Separating Fact From Fiction at Insider Monkey
01:27PM  The Threat and Risk of Rising Interest Rates: Separating Fact From Fiction
11:36AM  YouTube's Ad Controversy Not Going Away Yet; Will It Prove To Be Temporary?
09:40AM  Lyft becomes the latest major company to pull ads from 'offensive' YouTube at
12:17AM  PRESS DIGEST- New York Times business news - March 24 Reuters
Mar-23-17 07:25PM  J&J joins YouTube advertising boycott as Google struggles to contain crisis at
06:15PM  More big brands pull YouTube advertising AAP
05:59PM  Final Trade: VALE, JNJ & more
05:06PM  Why Google Needs to Forcefully Address Its Video Ad Problem
04:33PM  J&J, JPMorgan suspend YouTube ads over offensive videos
04:31PM  Google Breaks Support; Will YouTube Ad Flap Boost Facebook, TV Networks?
04:20PM  Google's Latest Content Controversy Is Messy, But Fixable
03:26PM  Investing Your Tax Refund Now Delivers Greater Returns
02:52PM  Johnson & Johnson Latest to Pull Ads From YouTube at TheStreet
01:35PM  Vox Media CEO: Google is going to be just fine
12:14PM  The 3 Best Big-Brand Stocks to Buy in 2017 at Motley Fool
09:47AM  Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
08:16AM  Markets eye critical health bill vote
12:35AM  PRESS DIGEST- New York Times business news - March 23 Reuters
Mar-22-17 03:34PM  Johnson & Johnson Is Due for a Pullback
03:21PM  Biotech giant plans $25M Tampa investment, 450 jobs at
02:47PM  Can Abbott Outperform Despite Alere?
Mar-21-17 05:26PM  FDA Links Breast Implants To A Rare Form Of Cancer
04:10PM  Johnson & Johnson to Host Investor Conference Call on First-Quarter Results PR Newswire
02:27PM  [$$] Funding Snapshot: Pulmocide Raises $30.4 Million Series B for Respiratory Drugs at The Wall Street Journal
12:05PM  Understanding Ionis Pharmaceuticals 2016 Revenue Stream
11:09AM  Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson at Motley Fool
08:09AM  4 Biotech Stocks With Jaw-Dropping Growth Potential at Motley Fool
Mar-20-17 06:07PM  3 Stocks I'll Hold Forever at Motley Fool
04:14PM  Will Apple Be the Next AAA-Rated Company?
04:13PM  What You Need to Know About the March Rate Hike
11:55AM  Forbes: Eight of the worlds billionaires call Tampa Bay home at
10:00AM  3 Stocks That Pay You to Own Them at Motley Fool
09:22AM  Blood Thinner Battle: Pfizer and Bristol-Myers Win at Investopedia
08:42AM  4 Stocks at 52-Week Highs That Are Still Worth Buying Today at Motley Fool
12:29AM  J&J CEO: US needs to focus on the long-term sustainability of health care at CNBC
12:08AM  A Prescription Blood Thinner Beat Aspirin at Preventing Recurrence of Blood Clots, Study Finds at The Wall Street Journal
Mar-19-17 11:43PM  World does better if US and China do better: J&J CEO
11:10AM  Compound Interest Is Real Modern-Day Alchemy
Mar-18-17 08:15AM  These Are The 5 Biggest S&P 500 Stocks In Buy Range Right Now
Mar-17-17 05:45PM  10 Reasons Johnson & Johnson Could Be the World's Most Perfect Stock at Motley Fool
01:39PM  Roche Restructuring Shows Trouble in US Diabetes Biz at Investopedia
09:27AM  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
06:00AM  With Tax Overhaul on Back Burner, Companies Embrace M&A Abroad
Mar-16-17 10:49AM  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
08:09AM  That Was Fast: Healthcare ETF Races To New Highs
Mar-15-17 06:29PM  US Market Indexes Gain and Fed Raises Rate
09:41AM  Why Pacira Pharmaceuticals Stock Is Already Up 56% This Year at Motley Fool
09:05AM  Johnson & Johnsons Financial Guidance for 2017
07:36AM  Johnson & Johnsons Major Developments
Mar-14-17 01:00PM  SXSW panel: IBM, Johnson & Johnson CEOs say tech, medicine collaboration offers huge upside at
11:00AM  Two-part Ebola vaccine offers long-lasting protection
10:36AM  Johnson & Johnsons Consumer Segment
09:06AM  Johnson & Johnsons Medical Devices Segment
07:36AM  Johnson & Johnsons Pharmaceuticals Segment
02:00AM  Johnson & Johnson Names Winners of First Africa Innovation Challenge PR Newswire
Mar-13-17 07:31PM  6 Signs of a Shareholder-Friendly Stock
06:23PM  US Market Indexes Mixed to Start the Week
12:50PM  9 Stocks in the CNBC IQ 100 Hit Highs at CNBC
11:48AM  New highs for the CNBC IQ 100
11:17AM  Ortho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test PR Newswire
10:37AM  Johnson & Johnsons Business Segment Performance
09:07AM  Johnson & Johnsons Revenue Trends
07:37AM  Johnson & Johnsons Valuation Compared to Its Peers
Mar-12-17 03:40PM  The 10 Most Important Tips for Playing the Stock Market in March
11:41AM  3 Big Pharma Stocks To Buy in Your 401(k) at Motley Fool
08:42AM  The 3 Most Important Numbers for Johnson & Johnson at Motley Fool
Mar-11-17 12:20PM  Trump Tax Plan Could Make Gold Great Again
Mar-10-17 03:28PM  JNJ To Face More Lawsuits This Year (JNJ) at Investopedia
02:21PM  Johnson & Johnson (JNJ): The Best Stock For Long Term Investors at Insider Monkey
09:40AM  US Market Indexes Close Higher
Mar-09-17 11:05PM  Asian shares mixed, Seoul up after Park impeachment affirmed
04:33PM  US STOCKS-Wall St ends up slightly; energy shares rebound Reuters
04:04PM  The Lawsuits Keep Coming for Johnson & Johnson
04:01PM  Johnson & Johnson, Intel Lead DJIA Higher Thursday
03:18PM  US STOCKS-Wall St slips as energy shares fall further; banks pare gains Reuters
12:46PM  The Contrarian: Is JNJ Worth the Premium? at Investopedia
11:57AM  The Risks and Double Compounding Potential
11:39AM  US STOCKS-S&P, Dow on track to snap 3-day losing streak as banks gain
10:21AM  Johnson & Johnson to Close UK Plant
Mar-08-17 04:23PM  1 Thing About Pfizer, Inc. Stock That You Might Be Overlooking at Motley Fool
02:26PM  4 Stocks That Will Likely Be Around in 50 Years
01:15PM  Turf maker under fire hires lawyer who investigated Brady
12:29PM  Results of Johnson & Johnson's Psoriasis Clinical Trials Impressive
07:25AM  Are Hedge Funds Turning Bearish on Healthcare Stocks? at Insider Monkey
Mar-07-17 05:58PM  Final Trade: VIAB, SPY & more
05:32PM  AAA Credit Rating Stocks in Focus: Microsoft Gurufocus
05:00PM  5 ways to trade health care after AHC unveil
12:47PM  5 Companies Hit 52-Week Highs
11:39AM  US STOCKS-Wall St pares losses as techs offset pharma decline
10:05AM  AAA Credit Rating Stocks in Focus: Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM